Shares of Biosig Technologies, Inc. (NYSE:BSGM) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $12.58 for the company, according to Zacks. Zacks has also assigned Biosig Technologies an industry rank of 76 out of 257 based on the ratings given to related companies.

Separately, Roth Capital reiterated a “buy” rating on shares of Biosig Technologies in a research report on Thursday.

Shares of BSGM stock traded down $0.09 on Friday, reaching $3.92. The company’s stock had a trading volume of 21,572 shares.

Biosig Technologies Company Profile

BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.

Further Reading: What is the Federal Reserve?

Get a free copy of the Zacks research report on Biosig Technologies (BSGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.